Harmony Biosciences (HRMY) Expected to Announce Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is projected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Harmony Biosciences to post earnings of $0.84 per share and revenue of $240.0360 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Harmony Biosciences Stock Up 0.4%

Harmony Biosciences stock opened at $36.01 on Tuesday. The business’s 50-day simple moving average is $37.48 and its two-hundred day simple moving average is $34.32. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75. The company has a market cap of $2.07 billion, a PE ratio of 11.32, a PEG ratio of 0.33 and a beta of 0.84. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $40.87.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of Harmony Biosciences stock in a transaction on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $35.92, for a total transaction of $752,919.12. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 50,640 shares of company stock valued at $1,932,256. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Harmony Biosciences

Institutional investors have recently modified their holdings of the business. Nebula Research & Development LLC raised its holdings in Harmony Biosciences by 2.0% in the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock worth $550,000 after purchasing an additional 348 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Harmony Biosciences by 2.4% in the second quarter. The Manufacturers Life Insurance Company now owns 22,686 shares of the company’s stock valued at $717,000 after purchasing an additional 532 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Harmony Biosciences by 30.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock valued at $100,000 after buying an additional 619 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Harmony Biosciences by 9.8% during the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock worth $266,000 after buying an additional 748 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of Harmony Biosciences by 0.3% during the 2nd quarter. Bank of America Corp DE now owns 270,220 shares of the company’s stock worth $8,539,000 after buying an additional 898 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HRMY. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Truist Financial dropped their price objective on shares of Harmony Biosciences from $48.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Oppenheimer reiterated an “outperform” rating and issued a $62.00 price objective on shares of Harmony Biosciences in a research note on Monday, November 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.63.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.